1. Home
  2. LAES vs ATYR Comparison

LAES vs ATYR Comparison

Compare LAES & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$2.48

Market Cap

821.2M

Sector

Technology

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.85

Market Cap

73.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
ATYR
Founded
2022
2005
Country
Switzerland
United States
Employees
N/A
58
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
821.2M
73.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
LAES
ATYR
Price
$2.48
$0.85
Analyst Decision
Buy
Hold
Analyst Count
1
8
Target Price
$7.00
$4.20
AVG Volume (30 Days)
6.6M
1.0M
Earning Date
03-31-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$64.88
N/A
Revenue Next Year
$94.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$0.64
52 Week High
$8.71
$7.29

Technical Indicators

Market Signals
Indicator
LAES
ATYR
Relative Strength Index (RSI) 30.73 50.70
Support Level N/A $0.67
Resistance Level $2.88 $0.85
Average True Range (ATR) 0.24 0.05
MACD -0.06 -0.00
Stochastic Oscillator 14.33 69.02

Price Performance

Historical Comparison
LAES
ATYR

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Share on Social Networks: